Explaining temporal trends in annualized relapse rates in placebo groups of randomized controlled trials in relapsing multiple sclerosis

Steinvorth, Simon Moritz

Systematic review, meta-analysis and meta-regression

dc.contributor.advisor	Friede, Tim Prof. Dr.
dc.contributor.author	Steinvorth, Simon Moritz
dc.date.accessioned	2014-01-21T07:52:05Z
dc.date.available	2014-01-28T23:50:04Z
dc.date.issued	2014-01-21
dc.identifier.uri	http://hdl.handle.net/11858/00-1735-0000-0022-5DFE-E
dc.identifier.uri	http://dx.doi.org/10.53846/goediss-4304
dc.language.iso	eng	de
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/3.0/
dc.subject.ddc	610	de
dc.title	Explaining temporal trends in annualized relapse rates in placebo groups of randomized controlled trials in relapsing multiple sclerosis	de
dc.title.alternative	Systematic review, meta-analysis and meta-regression	de
dc.type	doctoralThesis	de
dc.contributor.referee	Friede, Tim Prof. Dr.
dc.date.examination	2014-01-21
dc.description.abstracteng	Recent studies have shown a decrease in annualized relapse rates (ARRs) in placebo groups of randomized controlled trials (RCTs) in relapsing multiple sclerosis (RMS). This dissertation aimed to describe this trend in a different set of RCTs and to investigate whether patient baseline characteristics, eligibility criteria and other study design features could explain this phenomenon. A literature search of randomized, placebo-controlled trials in RMS offering data on relapses in placebo groups identified 56 suitable trials. Data on eligibility criteria and baseline characteristics were extracted and tested for significant trends over time. Several temporal trends were identified: The number of years considered for the calculation of pre-trial ARR as well as pre-trial ARRs themselves decreased, as did the duration of placebocontrolled follow-up. Pre-trial ARRs of the first and second preceding year before baseline showed major inconsistencies. Limits of eligible age as well as mean age increased, as did the mean disease duration, the number of eligibility criteria and the number of words and characters describing them, scores on the OQS, the number of treatment arms and the average number of patients per treatment arm. A meta-regression was conducted to estimate the contribution of these temporal trends to the decrease of trial ARRs over time. In the final meta-regression modeling of the trial placebo ARR, the date of publication was found to be insignificant in explaining the variation in trial placebo ARR, whereas pre-trial ARR, the number of years used to calculate pre-trial ARR, disease duration and the duration of follow-up became major contributors. In conclusion, the decline in trial ARRs most likely results from decreasing pre-trial ARRs and a shorter time period over which these were calculated. Increasing duration of illness may also contribute to the phenomenon.	de
dc.contributor.coReferee	Simons, Mikael Prof. Dr.
dc.contributor.thirdReferee	Oppermann, Martin Prof. Dr.
dc.subject.eng	multiple sclerosis	de
dc.subject.eng	relapsing	de
dc.subject.eng	placebo groups	de
dc.subject.eng	temporal trends	de
dc.subject.eng	systematic review	de
dc.subject.eng	meta-analysis	de
dc.subject.eng	meta-regression	de
dc.identifier.urn	urn:nbn:de:gbv:7-11858/00-1735-0000-0022-5DFE-E-8
dc.affiliation.institute	Medizinische Fakultät	de
dc.subject.gokfull	Medizin (PPN619874732)	de
dc.subject.gokfull	Medizinische Statistik / Biometrie / Epidemiologie - Allgemein- und Gesamtdarstellungen (PPN619875046)	de
dc.description.embargoed	2014-01-28
dc.identifier.ppn	776771981

Files in this item

Name:Dissertation Steinvorth.pdf

Size:3.077Mb

Format:PDF

Description:Dissertation

View/Open

Name:: Dissertation Steinvorth.pdf
Size:: 3.077Mb
Format:: PDF
Description:: Dissertation

View/Open

This item appears in the following Collection(s)

Human- und Zahnmedizin [2816]

Show simple item record